Outcome of Board meeting held on 10.02.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gayatri BioOrganics Limited's board approved unaudited financial results for Q3 FY26 (quarter ended Dec 31, 2025) and the nine-month period. The company reported zero revenue from operations across all periods shown. It posted a net loss of ₹21.71 lakhs for the quarter, slightly wider than the ₹16.06 lakh loss in the year-ago quarter. The nine-month loss stood at ₹69.13 lakhs versus ₹55.19 lakhs a year earlier. The company has a deeply negative networth of ₹(3,589.31) lakhs against a paid-up equity capital of ₹7,878.81 lakhs. The financial statements have been prepared on a going concern basis relying on a comfort letter from the promoters. The auditor (MGR & Co) issued an unqualified review report.
This is a distressed micro-cap with no operating revenue, recurring losses, and negative networth, meaning shareholders' equity is fully eroded. The stock carries high risk and remains viable only through continued promoter support as reflected in the going-concern comfort letter.